CorMedix Inc. to Participate in the Truist Securities BioPharma Symposium
CorMedix (Nasdaq: CRMD) announced its participation in the Truist Securities BioPharma Symposium scheduled for November 7, 2024, in New York City. The event will feature one-on-one meetings at the Lotte New York Palace Hotel. CorMedix is focused on commercializing DefenCath®, their lead product approved by the FDA in November 2023. The company has already launched DefenCath in inpatient settings in April 2024 and expanded to outpatient settings in July 2024. They plan to further develop DefenCath as a catheter lock solution for additional patient populations.
CorMedix (Nasdaq: CRMD) ha annunciato la sua partecipazione al Truist Securities BioPharma Symposium programmato per il 7 novembre 2024, nella città di New York. L'evento prevede incontri one-to-one presso il Lotte New York Palace Hotel. CorMedix si concentra sulla commercializzazione di DefenCath®, il loro prodotto di punta approvato dalla FDA nel novembre 2023. L'azienda ha già lanciato DefenCath in contesti di ricovero nel aprile 2024 ed è stata ampliata a contesti ambulatoriali nel luglio 2024. Prevedono di sviluppare ulteriormente DefenCath come soluzione di bloqueo del catetere per ulteriori popolazioni di pazienti.
CorMedix (Nasdaq: CRMD) anunció su participación en el Simposio BioPharma de Truist Securities programado para el 7 de noviembre de 2024, en la ciudad de Nueva York. El evento contará con reuniones uno a uno en el Lotte New York Palace Hotel. CorMedix se centra en la comercialización de DefenCath®, su producto principal aprobado por la FDA en noviembre de 2023. La empresa ya lanzó DefenCath en entornos de pacientes hospitalizados en abril de 2024 y se expandió a entornos ambulatorios en julio de 2024. Tienen planes de desarrollar aún más DefenCath como una solución de bloqueo de catéteres para poblaciones de pacientes adicionales.
CorMedix (Nasdaq: CRMD)는 2024년 11월 7일 뉴욕에서 예정된 Truist Securities BioPharma Symposium에 참여한다고 발표했습니다. 이 행사는 Lotte New York Palace Hotel에서 개인 미팅 형식으로 진행됩니다. CorMedix는 2023년 11월 FDA의 승인을 받은 주요 제품인 DefenCath®의 상용화에 집중하고 있습니다. 회사는 2024년 4월에 입원 환자 환경에서 DefenCath를 출시하였고, 2024년 7월에는 외래 환자 환경으로 확대하였습니다. 그들은 DefenCath를 추가 환자 집단을 위한 카테터 잠금 솔루션으로 더 개발할 계획입니다.
CorMedix (Nasdaq: CRMD) a annoncé sa participation au Symposium BioPharma de Truist Securities prévu pour le 7 novembre 2024 à New York. L'événement comportera des réunions individuelles à l'Hôtel Lotte New York Palace. CorMedix se concentre sur la commercialisation de DefenCath®, son produit phare approuvé par la FDA en novembre 2023. L'entreprise a déjà lancé DefenCath dans les établissements hospitaliers en avril 2024 et s'est étendue aux établissements ambulatoires en juillet 2024. Ils envisagent de développer davantage DefenCath en tant que solution de verrouillage de cathéter pour d'autres populations de patients.
CorMedix (Nasdaq: CRMD) hat seine Teilnahme am Truist Securities BioPharma Symposium angekündigt, das für den 7. November 2024 in New York City geplant ist. Die Veranstaltung wird Einzelgespräche im Lotte New York Palace Hotel umfassen. CorMedix konzentriert sich auf die Kommerzialisierung von DefenCath®, ihrem Hauptprodukt, das im November 2023 von der FDA genehmigt wurde. Das Unternehmen hat DefenCath bereits im April 2024 in stationären Einrichtungen eingeführt und im Juli 2024 auf ambulante Einrichtungen ausgeweitet. Sie planen, DefenCath weiter als Lösung zur Katheterverriegelung für weitere Patientengruppen zu entwickeln.
- None.
- None.
BERKELEY HEIGHTS, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that management will be participating in the Truist Securities BioPharma Symposium, taking place in New York City on Thursday, November 7, 2024.
| Truist Securities BioPharma Symposium | |
| Date: | Thursday, November 7, 2024 |
| Format: | 1x1 meetings |
| Location: | Lotte New York Palace Hotel, New York, NY |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath®, which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When did CorMedix (CRMD) launch DefenCath in outpatient settings?
What event is CorMedix (CRMD) participating in on November 7, 2024?
When did the FDA approve DefenCath for CorMedix (CRMD)?
When did CorMedix (CRMD) first launch DefenCath in inpatient settings?
